Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

In today’s episode,filmed live at the 43rd Annual CFS Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with breast cancer experts Kamel Abou Hussein, MD, and Victoria Rizk, MD, about the rapidly evolving therapeutic landscape in breast cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Abou Hussein is co-director of the Janet Knowles Breast Cancer, director of Breast Medical Oncology, and director of Breast Cancer Clinical Trials at Cooper University Health Care; as well as an assistant professor of medicine at Cooper Medical School of Rowan University in Camden, New Jersey. Dr Rizk is a medical oncologist at Tampa General Hospital Cancer Institute in Florida.

Their conversation explored the expanding role of antibody-drug conjugates (ADCs) across breast cancer subtypes, including how these agents are reshaping care for patients previously classified as having HER2-negative disease but are now recognized as having HER2-low or HER2-ultralow disease. The experts also discussed novel ADC targets under evaluation and how emerging findings from key phase 3 trials—such as ASCENT-03 (NCT05382299), ASCENT-04 (NCT05382286), and TROPION-Breast02 (NCT05374512)—may influence frontline treatment approaches in triple-negative breast cancer.

Additionally, their discussion reviewed the contemporary role of endocrine therapy, what is known about optimal sequencing and combinations with other therapeutic classes, and practical considerations for integrating new endocrine agents into routine practice to support personalized treatment decision-making.

Dr Levy added context to the discussion through his lung cancer expertise, facilitating a discussion that covered the differences and similarities between ADC use in the lung cancer and breast cancer treatment paradigms. The interview showcased the importance of broadening connections across oncology specialties to bring nuanced perspectives to clinical research and patient care.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding from AstraZeneca, Daiichi Sankyo, and Gilead; however, content is produced and independently developed by OncLive.